Prostate cancer is the most common non-skin cancer in American men. The current methods of screening for prostate cancer, which include digital rectal examinations (DREs) and serum levels of prostate specific antigen (PSA), do not detect many prostate tumors including some which are high grade and aggressive. In an effort to find better biomarkers for prostate cancer detect and prognosis. The San Antonio Center for Biomarkers of Risk of prostate cancer and genitourinary cancers (SABOR) was established in 2001. SABOR has gathered a population-based, minority-rich, cohort with extensive clinical data and biospecimens while tracking cancer-related outcomes. This cohort has been utilized for the discovery and validation of numerous new biomarkers for prostate cancer. Furthermore, specimens have been gathered for studies of bladder and kidney cancers that have been utilized by EDRN collaborators in biomarker discovery. In addition to these efforts, substantial progress has been made in the development and enhancement of the EDRN-PCPT Prostate Cancer Risk Calculator. The Risk Calculator uses numerous variables and biomarkers in addition to PSA and DRE to predict a man's risk of prostate cancer and, if detected, the chance of high-grade disease. In this current proposal, 3 specific aims are proposed: 1) We will conduct validation studies on promising serum-based biomarkers of prostate cancer;2) We will conduct validation studies of genomic markers of prostate cancer prognosis;3) We will employ results from our validation studies as well as EDRN-wide and other well-conducted validation studies to expand the applicability of the Prostate Cancer Risk Calculator, leading to individualized patient risk assessment. In support of these validation studies, the SABOR cohort will continue to be followed and additional biologies will be gathered on prostate cancer patients with long-term outcome data. In addition, the SABOR scientific personnel will continue to conduct EDRN Network validation studies, serve in leadership positions within the Network, and assist the EDRN with the design, conduct, and analysis of early detection validation studies that will alter the standard of care practice in the United States.

Agency
National Institute of Health (NIH)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA086402-15
Application #
8690783
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Kagan, Jacob
Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Texas Health Science Center
Department
Urology
Type
Schools of Medicine
DUNS #
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Kaz, Andrew M; Wong, Chao-Jen; Varadan, Vinay et al. (2016) Global DNA methylation patterns in Barrett's esophagus, dysplastic Barrett's, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use. Clin Epigenetics 8:111
Newcomb, Lisa F; Thompson Jr, Ian M; Boyer, Hilary D et al. (2016) Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol 195:313-20
Schenk, Jeannette M; Till, Cathee; Hsing, Ann W et al. (2016) Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control 27:175-82
Ankerst, Donna P; Xia, Jing; Thompson Jr, Ian M et al. (2015) Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. Eur Urol 68:1083-8
Wecksler, Aaron T; Hwang, Sung Hee; Liu, Jun-Yan et al. (2015) Biological evaluation of a novel sorafenib analogue, t-CUPM. Cancer Chemother Pharmacol 75:161-71
Alturkmani, Hani J; Pessetto, Ziyan Y; Godwin, Andrew K (2015) Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor. Expert Opin Investig Drugs 24:1045-58
Overholser, Stephen; Nielsen, Matthew; Torkko, Kathleen et al. (2015) Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing. J Urol 194:680-4
Yu, Ming; O'Leary, Rachele M; Kaz, Andrew M et al. (2015) Methylated B3GAT2 and ZNF793 Are Potential Detection Biomarkers for Barrett's Esophagus. Cancer Epidemiol Biomarkers Prev 24:1890-7
Gelfond, Jonathan; Choate, Kara; Ankerst, Donna P et al. (2015) Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening. J Urol 194:46-51
Peng, Haoran; Ishida, Masaharu; Li, Ling et al. (2015) Pseudogene INTS6P1 regulates its cognate gene INTS6 through competitive binding of miR-17-5p in hepatocellular carcinoma. Oncotarget 6:5666-77

Showing the most recent 10 out of 134 publications